Cilengitide Targeting of αvβ3 Integrin Receptor Synergizes with Radioimmunotherapy to Increase Efficacy and Apoptosis in Breast Cancer Xenografts
PA Burke, SJ DeNardo, LA Miers, KR Lamborn… - Cancer research, 2002 - AACR
Although metastatic breast cancer is responsive to radioimmunotherapy (RIT), a systemictargeted
radiation modality, complete and permanent remissions are not typical with single-…
radiation modality, complete and permanent remissions are not typical with single-…
Development of Tumor Targeting Bioprobes (111In-Chimeric L6 Monoclonal Antibody Nanoparticles) for Alternating Magnetic Field Cancer Therapy
SJ DeNardo, GL DeNardo, LA Miers, A Natarajan… - Clinical cancer …, 2005 - AACR
Objectives: 111 In-chimeric L6 (ChL6) monoclonal antibody (mAb)–linked iron oxide nanoparticle
(bioprobes) pharmacokinetics, tumor uptake, and the therapeutic effect of inductively …
(bioprobes) pharmacokinetics, tumor uptake, and the therapeutic effect of inductively …
Thermal dosimetry predictive of efficacy of 111In-ChL6 nanoparticle AMF–induced thermoablative therapy for human breast cancer in mice
…, GL DeNardo, A Natarajan, LA Miers… - Journal of Nuclear …, 2007 - Soc Nuclear Med
Antibody (mAb)-linked iron oxide nanoparticles (bioprobes) provide the opportunity to develop
tumor specific thermal therapy (Rx) for metastatic cancer when inductively heated by an …
tumor specific thermal therapy (Rx) for metastatic cancer when inductively heated by an …
Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates
…, GL DeNardo, SJ DeNardo, GR Mirick, LA Miers… - Cancer research, 1995 - AACR
Trial therapy for lyphoma with the radiolabeled chelate-antibody conjugate 67 Cu-2IT-BAT-Lym-1
has been promising. It is desirable to deliver therapeutic doses of radiometal using a …
has been promising. It is desirable to deliver therapeutic doses of radiometal using a …
Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts
…, KR Lamborn, LA Miers… - Proceedings of the …, 1997 - National Acad Sciences
Synergistic multimodality therapy is needed for breast cancer. Breast cancer frequently has
p53 mutations that result in cells less likely to undergo apoptosis when exposed to DNA …
p53 mutations that result in cells less likely to undergo apoptosis when exposed to DNA …
Comparison of 1, 4, 7, 10-tetraazacyclododecane-N, N', N'', N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2 …
…, S Shen, KR Lamborn, JJ Peterson, LA Miers… - Clinical cancer research …, 1998 - AACR
Radioimmunotherapy using 131I-ChL6 antibody has shown promise in patients with breast
cancer. To enhance this potential, a novel ChL6 immunoconjugate that is catabolizable and …
cancer. To enhance this potential, a novel ChL6 immunoconjugate that is catabolizable and …
Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium‐DOTA‐peptide‐ChL6
RT O'Donnell, SJ DeNardo, LA Miers… - The …, 2002 - Wiley Online Library
BACKGROUND Therapy for prostate cancer in the PC3 tumor‐nude mouse model with 90
yttrium‐( 90 Y)‐DOTA‐peptide‐ChL6 (5.55 MBq;150 μCi) has resulted in durable responses. …
yttrium‐( 90 Y)‐DOTA‐peptide‐ChL6 (5.55 MBq;150 μCi) has resulted in durable responses. …
Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji).
…, CF Meares, SC Srivastava, LA Miers… - Clinical cancer research …, 1997 - AACR
Radioimmunotherapy has shown promising results for treatment of radiosensitive
malignancies such as lymphoma. Positive responses have been reported in patients with non-…
malignancies such as lymphoma. Positive responses have been reported in patients with non-…
Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of90Y-DOTA-peptide-Lym-1 in lymphoma …
JM Tuscano, RT O'Donnell, LA Miers… - Blood, The Journal …, 2003 - ashpublications.org
CD22 is a membrane glycophosphoprotein found on nearly all healthy B-lymphocytes and
most B-cell lymphomas. Recent in vitro studies have identified several anti-CD22 monoclonal …
most B-cell lymphomas. Recent in vitro studies have identified several anti-CD22 monoclonal …
Combined modality radioimmunotherapy: promise and peril
PA Burke, SJ DeNardo, LA Miers… - … Journal of the …, 2002 - Wiley Online Library
BACKGROUND Single‐agent radioimmunotherapy (RIT), although potentially useful for
slowing solid tumor growth, has not been effective in curing aggressive tumors, such as breast …
slowing solid tumor growth, has not been effective in curing aggressive tumors, such as breast …